Literature DB >> 11953596

Angiogenic cytokines in cartilage tumors.

Richard L McGough1, Chuzhao Lin, Patricia Meitner, Bassam I Aswad, Richard M Terek.   

Abstract

Pathologic neovascularization has been described in numerous types of cancers. The angiogenic cytokines vascular endothelial growth factor and basic fibroblast growth factor are thought to be the primary inducers of angiogenesis in these tumors. Hypoxia-inducible transcription factor is a nuclear transcription factor that promotes vascular endothelial growth factor expression. Prior studies have shown pathologic neovascularization in chondrosarcoma, which correlates with pathologic grade of the tumor. Angiogenic and nonangiogenic cartilage tumors were studied for expression of vascular endothelial growth factor, basic fibroblast growth factor and hypoxia-inducible transcription factors by immunohistochemistry and Northern blot analysis. Expression of vascular endothelial growth factor and hypoxia-inducible transcription factor were increased significantly in angiogenic tumors. Fibroblast growth factor expression was similar in angiogenic and nonangiogenic specimens. This may have implications for tumor grading and surgical decision-making, and potential treatment with antiangiogenesis chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11953596     DOI: 10.1097/00003086-200204000-00009

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  12 in total

Review 1.  Cartilage tumours and bone development: molecular pathology and possible therapeutic targets.

Authors:  Judith V M G Bovée; Pancras C W Hogendoorn; Jay S Wunder; Benjamin A Alman
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  miR-181a Targets RGS16 to Promote Chondrosarcoma Growth, Angiogenesis, and Metastasis.

Authors:  Xiaojuan Sun; Cherie Charbonneau; Lei Wei; Qian Chen; Richard M Terek
Journal:  Mol Cancer Res       Date:  2015-05-26       Impact factor: 5.852

3.  CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis.

Authors:  Xiaojuan Sun; Cherie Charbonneau; Lei Wei; Wentian Yang; Qian Chen; Richard M Terek
Journal:  Mol Cancer Ther       Date:  2013-05-17       Impact factor: 6.261

4.  MicroRNA regulates vascular endothelial growth factor expression in chondrosarcoma cells.

Authors:  Xiaojuan Sun; Lei Wei; Qian Chen; Richard M Terek
Journal:  Clin Orthop Relat Res       Date:  2015-03       Impact factor: 4.176

5.  HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity.

Authors:  Xiaojuan Sun; Lei Wei; Qian Chen; Richard M Terek
Journal:  J Biol Chem       Date:  2009-06-09       Impact factor: 5.157

6.  Diversity of angiogenesis among malignant bone tumors.

Authors:  Tadahiko Kubo; Shoji Shimose; Jun Fujimori; Koji Arihiro; Mitsuo Ochi
Journal:  Mol Clin Oncol       Date:  2012-08-10

7.  Analysis of angiogenic factors and cyclooxygenase-2 expression in cartilaginous tumors- clinical and histological correlation.

Authors:  Francisco Fontes Cintra; Mauricio Etchebehere; José Carlos Barbi Gonçalves; Alejandro Enzo Cassone; Eliane Maria Ingrid Amstalden
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

8.  The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets.

Authors:  E David; F Blanchard; M F Heymann; G De Pinieux; F Gouin; F Rédini; D Heymann
Journal:  Sarcoma       Date:  2011-05-22

9.  CXCR4 and axillary lymph nodes: review of a potential biomarker for breast cancer metastasis.

Authors:  David Hiller; Quyen D Chu
Journal:  Int J Breast Cancer       Date:  2011-08-23

10.  CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression.

Authors:  Xiaojuan Sun; Lei Wei; Qian Chen; Richard M Terek
Journal:  Mol Cancer       Date:  2010-01-26       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.